Chardan Capital Expects Lower Earnings for Dyne Therapeutics

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Stock analysts at Chardan Capital cut their FY2024 earnings per share estimates for Dyne Therapeutics in a report released on Wednesday, November 13th. Chardan Capital analyst K. Nakae now forecasts that the company will earn ($3.14) per share for the year, down from their previous estimate of ($2.75). Chardan Capital currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.39) per share. Chardan Capital also issued estimates for Dyne Therapeutics’ FY2025 earnings at ($2.73) EPS.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25).

Other research analysts have also issued reports about the stock. Guggenheim boosted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Morgan Stanley increased their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Oppenheimer reaffirmed an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Stifel Nicolaus increased their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $29.34 on Monday. Dyne Therapeutics has a 1 year low of $10.03 and a 1 year high of $47.45. The firm has a fifty day moving average of $32.42 and a 200-day moving average of $35.26. The company has a market cap of $2.99 billion, a price-to-earnings ratio of -8.24 and a beta of 1.10.

Insider Activity

In related news, Director Jason P. Rhodes sold 782 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $33.10, for a total transaction of $25,884.20. Following the completion of the sale, the director now directly owns 15,962 shares in the company, valued at approximately $528,342.20. This trade represents a 4.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the transaction, the senior vice president now owns 98,568 shares in the company, valued at approximately $3,405,524.40. This trade represents a 1.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 176,257 shares of company stock worth $6,193,718 over the last 90 days. 20.77% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC raised its holdings in shares of Dyne Therapeutics by 4.3% during the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after acquiring an additional 352 shares during the period. Nisa Investment Advisors LLC raised its stake in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Dyne Therapeutics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock valued at $123,000 after purchasing an additional 709 shares during the period. KBC Group NV lifted its holdings in shares of Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares in the last quarter. Finally, Amalgamated Bank boosted its position in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after buying an additional 796 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.